Short Summary
Samsung has filed an IPR petition challenging Mobile Data Technologies' 9,619,578 patent covering mobile content sharing. The petition argues the claims are obvious over prior art combinations and seeks institution of the review.
Detailed Summary
Samsung Electronics Co. Ltd. and Samsung Electronics America, Inc. have petitioned the PTAB for inter partes review of Mobile Data Technologies LLC's U.S. Patent No. 9,619,578, which claims methods and apparatus for capturing media on a mobile device, integrating it with wireless networking information, and inserting it into an application‑based information channel. The petition asserts that claims 1, 6‑12, 15‑19, 21‑22 are unpatentable under 35 U.S.C. §103, relying on two prior‑art combinations: Randall‑Forsyth (forum services on Symbian devices) and Pelkey‑Eck (portable gaming systems with messaging and camera capabilities). It also disputes the patent owner’s narrow claim constructions and argues that discretionary denial under §§314(a) and 325(d) is improper. No institution decision has yet been made.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Samsung Electronics Co. Ltd., et al. vs Mobile Data Technologies LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Dyson Technology Limited et al.vsOmachron Intellectual Property Inc. et al.
Dyson and Omachron have settled their IPR dispute over U.S. Patent 7,776,120 and jointly request the Board to terminate the proceeding while keeping the settlement agreement confidential.
United Services Automobile AssociationvsAuto Telematics Ltd.
The USPTO denied USAA's request for Director Review of the institution decision in IPR2025-00812, leaving the institution of the auto‑telematics patent intact.
SAMSUNG ELECTRONICS CO., LTD. et al.vsOMNI MEDSCI, INC.
Apple (as petitioner) secured a partial victory over Omni MedSci's wearable health‑monitoring patent, finding 12 of the 23 claims unpatentable while leaving 11 claims intact.
Abbott Laboratories et al.vsMIRACOR MEDICAL SA
The USPTO denied Abbott Laboratories’ request for Director Review of the institution decisions in three IPRs, leaving Miracor Medical’s patent 11,572,879 in place.
Meta Platforms, Inc.vsDialect, LLC
Meta Platforms petitions the PTAB to invalidate claims 1,4,6‑9 of U.S. Patent 7,398,209, alleging obviousness over multiple speech‑recognition and natural‑language prior arts. The petition lists five grounds invoking 35 U.S.C. § 103.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.